Sign In
Buy ACB
Aurora Cannabis Earnings Calls
| Release date | Aug 05, 2026 |
| EPS estimate | -$0.130 |
| EPS actual | - |
| Revenue estimate | 48.476M |
| Revenue actual | - |
| Expected change | +/- 12.69% |
| Release date | Jun 11, 2026 |
| EPS estimate | -$0.0700 |
| EPS actual | $0.0700 |
| EPS Surprise | 200.00% |
| Revenue estimate | 54.42M |
| Revenue actual | 60.976M |
| Revenue Surprise | 12.05% |
| Release date | Feb 04, 2026 |
| EPS estimate | $0.0972 |
| EPS actual | $0.0900 |
| EPS Surprise | -7.42% |
| Revenue estimate | 67.264M |
| Revenue actual | 68.59M |
| Revenue Surprise | 1.97% |
| Release date | Nov 05, 2025 |
| EPS estimate | $0.0300 |
| EPS actual | $0.0900 |
| EPS Surprise | 200.00% |
| Revenue estimate | 88.35M |
| Revenue actual | 63.236M |
| Revenue Surprise | -28.43% |
Last 4 Quarters for Aurora Cannabis
Below you can see how ACB performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Nov 05, 2025 |
| Price on release | $4.46 |
| EPS estimate | $0.0300 |
| EPS actual | $0.0900 |
| EPS surprise | 200.00% |
| Date | Price |
|---|---|
| Oct 30, 2025 | $4.81 |
| Oct 31, 2025 | $4.95 |
| Nov 03, 2025 | $4.88 |
| Nov 04, 2025 | $4.54 |
| Nov 05, 2025 | $4.46 |
| Nov 06, 2025 | $4.36 |
| Nov 07, 2025 | $4.55 |
| Nov 10, 2025 | $4.67 |
| Nov 11, 2025 | $4.55 |
| 4 days before | -7.28% |
| 4 days after | 2.02% |
| On release day | -2.24% |
| Change in period | -5.41% |
| Release date | Feb 04, 2026 |
| Price on release | $3.75 |
| EPS estimate | $0.0972 |
| EPS actual | $0.0900 |
| EPS surprise | -7.42% |
| Date | Price |
|---|---|
| Jan 29, 2026 | $4.18 |
| Jan 30, 2026 | $4.06 |
| Feb 02, 2026 | $3.92 |
| Feb 03, 2026 | $4.06 |
| Feb 04, 2026 | $3.75 |
| Feb 05, 2026 | $3.31 |
| Feb 06, 2026 | $3.48 |
| Feb 09, 2026 | $3.59 |
| Feb 10, 2026 | $3.56 |
| 4 days before | -10.29% |
| 4 days after | -5.07% |
| On release day | -11.73% |
| Change in period | -14.83% |
| Release date | Jun 11, 2026 |
| Price on release | $3.08 |
| EPS estimate | -$0.0700 |
| EPS actual | $0.0700 |
| EPS surprise | 200.00% |
| Date | Price |
|---|---|
| Jun 05, 2026 | $3.38 |
| Jun 08, 2026 | $3.41 |
| Jun 09, 2026 | $3.38 |
| Jun 10, 2026 | $3.29 |
| Jun 11, 2026 | $3.08 |
| Jun 12, 2026 | $3.04 |
| Jun 15, 2026 | $2.95 |
| Jun 16, 2026 | $3.00 |
| Jun 17, 2026 | $2.92 |
| 4 days before | -8.88% |
| 4 days after | -5.19% |
| On release day | -1.30% |
| Change in period | -13.61% |
| Release date | Aug 05, 2026 |
| Price on release | - |
| EPS estimate | -$0.130 |
| EPS actual | - |
| Date | Price |
|---|---|
| Jun 25, 2026 | $2.76 |
| Jun 26, 2026 | $2.83 |
| Jun 29, 2026 | $2.88 |
| Jun 30, 2026 | $2.79 |
| Jul 01, 2026 | $2.81 |
Aurora Cannabis Earnings Call Transcript Summary of Q1 2026
Aurora reported a strong Q1 FY2026 with revenue of $98M (up 17% YoY) driven by a 37% increase in global medical cannabis revenue and 85% growth in international sales. Adjusted gross margin improved sharply to 52% (up 1,000 bps) and adjusted EBITDA more than doubled to ~$11M; free cash flow was positive $9.2M. The company highlights its leadership in high‑margin global medical cannabis markets (Canada, Australia, Germany, Poland, U.K.), multiple GMP/TGA‑certified facilities, a flexible balance sheet with $186M cash and no cannabis business debt, and no need for dilutive ATM financing. Management emphasized product quality, regulatory and distribution advantages, yield/cost improvements, and selective use of third‑party sourcing. Guidance: Q2 revenue expected to grow year‑over‑year (global medical cannabis +8% to +12%), consolidated adjusted gross margins to increase, and adjusted EBITDA to remain positive and grow versus Q1. Notable headwinds noted were one‑off plant propagation margin impacts and higher SG&A tied to variable distribution costs and integration of acquired operations (MedReleaf/MedRelief), which management views as appropriate going forward. Management is confident regulatory developments in markets like Germany would likely favor experienced, compliant operators.
